JASCAYD
LaunchNDAORALTABLETPriority Review
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JASCAYD (nerandomilast) is an oral small-molecule PDE4B-selective inhibitor approved for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) in adults. It works by inhibiting phosphodiesterase 4 (PDE4), which elevates intracellular cAMP and reduces profibrotic growth factors and inflammatory cytokines. The drug offers both antifibrotic and immunomodulatory effects targeting the underlying pathology of progressive fibrotic lung diseases.
Launch
Recent launch with moderate competitive pressure (30/100) creates growth opportunities for commercial teams building market presence in IPF/PPF segments.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JASCAYD is a recently launched specialty pharma asset in a high-value rare disease indication (IPF/PPF), offering early-career professionals opportunities in launch strategy, pulmonology sales, and market access. Team size and career progression will depend on commercial success and Boehringer Ingelheim's investment level in the product.
Brand ManagerMedical Science Liaison
Worked on JASCAYD at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.